Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.33 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | RRM1 | P23921 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24172604 | 1.00 | C3AR1 (0.35) | C3AR1DPP7SIRT6SIRT1FOLH1 | |
| SCHEMBL22800674 | 0.95 | SIRT6 (0.37) | C3AR1DPP7SIRT6SIRT1FOLH1 | |
| SCHEMBL20104622 | 0.88 | NPY4R (0.35) | DPP7SIRT6SIRT1SMN1; SMN2 | |
| SCHEMBL24015397 | 0.86 | FURIN (0.36) | C3AR1DPP7SIRT6SIRT1SMN1; SMN2 | |
| SCHEMBL19101872 | 0.86 | FURIN (0.36) | C3AR1DPP7SIRT6SIRT1SMN1; SMN2 | |
| SCHEMBL27410441 | 0.83 | C3AR1 (0.48) | C3AR1FOLH1CTDSP1 | |
| SCHEMBL9069536 | 0.83 | C3AR1 (0.48) | C3AR1FOLH1CTDSP1 | |
| SCHEMBL24172621 | 0.83 | C3AR1 (0.36) | C3AR1DPP7SIRT6SIRT1FOLH1 | |
| SCHEMBL22702612 | 0.82 | C3AR1 (0.36) | C3AR1DPP7SIRT6SIRT1FOLH1 | |
| SCHEMBL13993614 | 0.82 | C3AR1 (0.36) | C3AR1DPP7SIRT6SIRT1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300962-A1 | LIPID PRODRUGS OF PREGNANE NEUROSTEROIDS AND USES THEREOF | SEAPORT THERAPEUTICS, INC. | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300962-A1 | LIPID PRODRUGS OF PREGNANE NEUROSTEROIDS AND USES THEREOF | CYP21A2, CYP46A1, CYP17A1 | C3AR1 602/4885DPP7 2177/4885SIRT6 2972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.